{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:36:15Z","timestamp":1790883375428,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004245","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000}}],"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UK Health Security Agency"},{"DOI":"10.13039\/100018336","name":"National Institute for Health Research Health Protection Research Unit","doi-asserted-by":"publisher","award":["Grant Reference NIHR200929"],"award-info":[{"award-number":["Grant Reference NIHR200929"]}],"id":[{"id":"10.13039\/100018336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"\n Background<\/jats:title>\n An increased risk of myocarditis or pericarditis after priming with mRNA Coronavirus Disease 2019 (COVID-19) vaccines has been shown but information on the risk post-booster is limited. With the now high prevalence of prior Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, we assessed the effect of prior infection on the vaccine risk and the risk from COVID-19 reinfection.<\/jats:p>\n <\/jats:sec>\n \n Methods and findings<\/jats:title>\n \n We conducted a self-controlled case series analysis of hospital admissions for myocarditis or pericarditis in England between 22 February 2021 and 6 February 2022 in the 50 million individuals eligible to receive the adenovirus-vectored vaccine (ChAdOx1-S) for priming or an mRNA vaccine (BNT162b2 or mRNA-1273) for priming or boosting. Myocarditis and pericarditis admissions were extracted from the Secondary Uses Service (SUS) database in England and vaccination histories from the National Immunisation Management System (NIMS); prior infections were obtained from the UK Health Security Agency\u2019s Second-Generation Surveillance Systems. The relative incidence (RI) of admission within 0 to 6 and 7 to 14 days of vaccination compared with periods outside these risk windows stratified by age, dose, and prior SARS-CoV-2 infection for individuals aged 12 to 101 years was estimated. The RI within 27 days of an infection was assessed in the same model. There were 2,284 admissions for myocarditis and 1,651 for pericarditis in the study period. Elevated RIs were only observed in 16- to 39-year-olds 0 to 6 days postvaccination, mainly in males for myocarditis. Both mRNA vaccines showed elevated RIs after first, second, and third doses with the highest RIs after a second dose 5.34 (95% confidence interval (CI) [3.81, 7.48];\n p<\/jats:italic>\n < 0.001) for BNT162b2 and 56.48 (95% CI [33.95, 93.97];\n p<\/jats:italic>\n < 0.001) for mRNA-1273 compared with 4.38 (95% CI [2.59, 7.38];\n p<\/jats:italic>\n < 0.001) and 7.88 (95% CI [4.02, 15.44];\n p<\/jats:italic>\n < 0.001), respectively, after a third dose. For ChAdOx1-S, an elevated RI was only observed after a first dose, RI 5.23 (95% CI [2.48, 11.01];\n p<\/jats:italic>\n < 0.001). An elevated risk of admission for pericarditis was only observed 0 to 6 days after a second dose of mRNA-1273 vaccine in 16 to 39 year olds, RI 4.84 (95% CI [1.62, 14.01];\n p<\/jats:italic>\n = 0.004). RIs were lower in those with a prior SARS-CoV-2 infection than in those without, 2.47 (95% CI [1.32,4.63];\n p<\/jats:italic>\n = 0.005) versus 4.45 (95% [3.12, 6.34];\n p<\/jats:italic>\n = 0.001) after a second BNT162b2 dose, and 19.07 (95% CI [8.62, 42.19];\n p<\/jats:italic>\n < 0.001) versus 37.2 (95% CI [22.18, 62.38];\n p<\/jats:italic>\n < 0.001) for mRNA-1273 (myocarditis and pericarditis outcomes combined). RIs 1 to 27 days postinfection were elevated in all ages and were marginally lower for breakthrough infections, 2.33 (95% CI [1.96, 2.76];\n p<\/jats:italic>\n < 0.001) compared with 3.32 (95% CI [2.54, 4.33];\n p<\/jats:italic>\n < 0.001) in vaccine-na\u00efve individuals respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n We observed an increased risk of myocarditis within the first week after priming and booster doses of mRNA vaccines, predominantly in males under 40 years with the highest risks after a second dose. The risk difference between the second and the third doses was particularly marked for the mRNA-1273 vaccine that contains half the amount of mRNA when used for boosting than priming. The lower risk in those with prior SARS-CoV-2 infection, and lack of an enhanced effect post-booster, does not suggest a spike-directed immune mechanism. Research to understand the mechanism of vaccine-associated myocarditis and to document the risk with bivalent mRNA vaccines is warranted.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004245","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T13:36:05Z","timestamp":1686144965000},"page":"e1004245","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3999-6461","authenticated-orcid":true,"given":"Julia","family":"Stowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1884-0097","authenticated-orcid":true,"given":"Elizabeth","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5833-1863","authenticated-orcid":true,"given":"Heather J.","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"pmed.1004245.ref001","article-title":"Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control study","author":"J Stowe","year":"2022","journal-title":"MedRxiv"},{"key":"pmed.1004245.ref002","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7104e3","article-title":"Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19\u2013Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance\u2014VISION Network, 10 States, August 2021\u2013January 2022","volume":"71","author":"MG Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"23","key":"pmed.1004245.ref003","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel","volume":"385","author":"D Mevorach","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"pmed.1004245.ref004","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting","volume":"385","author":"N Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"pmed.1004245.ref005","doi-asserted-by":"crossref","first-page":"e068665","DOI":"10.1136\/bmj-2021-068665","article-title":"SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study","volume":"375","author":"A Husby","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"pmed.1004245.ref006","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamacardio.2022.0583","article-title":"SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents","volume":"7","author":"\u00d8 Karlstad","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"10342","key":"pmed.1004245.ref007","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/S0140-6736(22)00791-7","article-title":"Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases","volume":"399","author":"HL Wong","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"pmed.1004245.ref008","doi-asserted-by":"crossref","first-page":"e1004056","DOI":"10.1371\/journal.pmed.1004056","article-title":"Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study","volume":"19","author":"M Massari","year":"2022","journal-title":"PLoS Med"},{"issue":"16","key":"pmed.1004245.ref009","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1001\/jama.2022.4425","article-title":"Myocarditis Following a Third BNT162b2 Vaccination Dose in Military Recruits in Israel","volume":"327","author":"L Friedensohn","year":"2022","journal-title":"JAMA"},{"key":"pmed.1004245.ref010","doi-asserted-by":"crossref","first-page":"839090","DOI":"10.3389\/fcvm.2022.839090","article-title":"A Case Series of Myocarditis Following Third (Booster) Dose of COVID-19 Vaccination: Magnetic Resonance Imaging Study","volume":"9","author":"A Shiyovich","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"pmed.1004245.ref011","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.amjcard.2022.02.039","article-title":"Myopericarditis After COVID-19 Booster Dose Vaccination","volume":"172","author":"KA Sharff","year":"2022","journal-title":"Am J Cardiol"},{"issue":"2","key":"pmed.1004245.ref012","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"M Patone","year":"2022","journal-title":"Nat Med"},{"key":"pmed.1004245.ref013","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.122.059970","article-title":"Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex","volume":"146","author":"M Patone","year":"2022","journal-title":"Circulation"},{"key":"pmed.1004245.ref014","doi-asserted-by":"crossref","first-page":"ehab901","DOI":"10.1093\/eurheartj\/ehab901","article-title":"Myocarditis after BNT162b2 mRNA SARS-CoV-2 vaccine: low incidence and mild severity","author":"G Liuzzo","year":"2022","journal-title":"Eur Heart J"},{"issue":"10","key":"pmed.1004245.ref015","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/sim.2302","article-title":"Tutorial in biostatistics: the self-controlled case series method","volume":"25","author":"HJ Whitaker","year":"2006","journal-title":"Stat Med"},{"key":"pmed.1004245.ref016","doi-asserted-by":"crossref","first-page":"100260","DOI":"10.1016\/j.lanepe.2021.100260","article-title":"Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1-S and BNT162b2 COVID-19 vaccines: A national cohort study in England","volume":"13","author":"NJ Andrews","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"42","key":"pmed.1004245.ref017","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The task force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"European Society of Cardiology (ESC)","year":"2015","journal-title":"Eur Heart J"},{"issue":"45","key":"pmed.1004245.ref018","doi-asserted-by":"crossref","first-page":"E1529","DOI":"10.1503\/cmaj.220676","article-title":"Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study","volume":"194","author":"Z Naveed","year":"2022","journal-title":"CMAJ"},{"key":"pmed.1004245.ref019","article-title":"Risk of Myocarditis after Covid-19 mRNA Vaccination: Impact of Booster Dose and Dosing Interval","author":"A St\u00e9phane Le Vu","journal-title":"medRxiv"},{"key":"pmed.1004245.ref020","article-title":"Booster Vaccination with SARS-CoV-2 mRNA Vaccines and Myocarditis Risk in Adolescents and Young Adults: A Nordic Cohort Study of 8.9 Million Residents","author":"A Hviid","year":"2022","journal-title":"medRxiv"},{"key":"pmed.1004245.ref021","unstructured":"The Moderna COVID-19 (mRNA-1273) vaccine: What you need to know. World Health Organisation Newsroom. 18 August 2022. Available from: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know#:~:text=What\u2019s%20the%20recommended%20dosage%3F,given%20intramuscularly%2C%204%20weeks%20apart (accessed 2023 Apr 24)."},{"key":"pmed.1004245.ref022","article-title":"Myocarditis and COVID-19 mRNA vaccines: a mechanistic hypothesis involving dsRNA","author":"G Milano","year":"2021","journal-title":"Future Virol"},{"issue":"7","key":"pmed.1004245.ref023","doi-asserted-by":"crossref","first-page":"ytac290","DOI":"10.1093\/ehjcr\/ytac290","article-title":"Fulminant myocarditis after the first dose of mRNA-1273 vaccination in a patient with previous COVID-19: a case report","volume":"6","author":"K Horiuchi","year":"2022","journal-title":"Eur Heart J Case Rep"},{"key":"pmed.1004245.ref024","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/jamacardio.2021.2833","article-title":"Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military","volume":"6","author":"J Montgomery","year":"2021","journal-title":"JAMA Cardiol"},{"key":"pmed.1004245.ref025","first-page":"100774","article-title":"Temporal relation between second dose BNT162b2 mRNA COVID-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection","volume":"34","author":"E Ammirati","year":"2021","journal-title":"Int J Cardiol Heart Vasc"},{"key":"pmed.1004245.ref026","doi-asserted-by":"crossref","first-page":"876533","DOI":"10.3389\/fimmu.2022.876533","article-title":"Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Na\u00efve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals","volume":"13","author":"M Ogri\u010d","year":"2022","journal-title":"Front Immunol"},{"issue":"10267","key":"pmed.1004245.ref027","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1-S nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"MN Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"25","key":"pmed.1004245.ref028","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"EE Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"pmed.1004245.ref029","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","article-title":"A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine","volume":"39","author":"L Chu","year":"2021","journal-title":"Vaccine"},{"issue":"3","key":"pmed.1004245.ref030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/vaccines10030459","article-title":"SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated South African Healthcare Workers","volume":"10","author":"On Behalf Of The Wits Vida Hcw Study Group","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"pmed.1004245.ref031","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1002\/sim.9179","article-title":"Avoiding bias in self-controlled case series studies of coronavirus disease 2019","volume":"40","author":"O Fonseca-Rodr\u00edguez","year":"2021","journal-title":"Stat Med"},{"issue":"1","key":"pmed.1004245.ref032","doi-asserted-by":"crossref","first-page":"e000373","DOI":"10.1136\/bmjmed-2022-000373","article-title":"Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study","volume":"2","author":"A Husby","year":"2023","journal-title":"BMJ Med"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004245","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T13:41:49Z","timestamp":1687527709000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004245","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]}}}